Bristol-Myers Squibb Price Target Cut to $41.00 by Analysts at Jefferies Group (BMY)
Equities researchers at Jefferies Group reduced their target price on shares of Bristol-Myers Squibb (NYSE:BMY) from $45.00 to $41.00 in a research report issued on Tuesday, Analyst Ratings Network.com reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price objective points to a potential downside of 3.57% from the stock’s previous close.
Bristol-Myers Squibb (NYSE:BMY) traded up 0.52% on Tuesday, hitting $42.52. 4,672,928 shares of the company’s stock traded hands. Bristol-Myers Squibb has a one year low of $30.64 and a one year high of $49.57. The stock’s 50-day moving average is $42.89 and its 200-day moving average is $42.45. The company has a market cap of $70.002 billion and a P/E ratio of 51.65.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, July 25th. The company reported $0.44 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.45 by $0.01. The company had revenue of $4.05 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was down 8.9% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post $1.74 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb (NYSE:BMY) in a research note to investors on Wednesday, September 4th.
Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $44.73.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.